PubMed Health⌕ Search

Biomedical subjects

E Westin

Publications and source records attributed to E Westin.

18 recordsLinked to original sources
PubMed2000

Factors influencing success of monovision contact lens fitting: survey of contact lens diplomates.

BACKGROUND: Contact lenses are frequently fitted so that one eye is focused for distance and the other for near (monovision) in order to reduce the dependence of presbyopic patients on bifocal spectacle correction. METHODS: We surveyed Diplomates in the Cornea and Contact Lens section of the American Academy of Optometry (N = 179) regarding their estimates of success with monovision fitting and factors influencing their perception of success. Results were statistically analyzed to determine the fitting philosophies of responders estimating that they achieve high success rates (HSRs) and low success rates (LSRs), respectively. RESULTS: Completed surveys were returned by 98 Diplomates (54.8%), who estimated an overall success rate of approximately 71.7% with monovision; 50.5% "totally successful" (wear monovision correction full-time without problems or need for additional correction) and 21.2% "successful" (wear monovision full-time, but experience some symptoms of blur or other discomfort, may wear over-correction at times for driving or detailed near work). Sighting dominance was the most frequently used method to determine the distant eye, followed by the plus-lens test. The HSR group tended to be more likely to take occupational factors into account when deciding which eye to use for the distance lens, and they used more flexibility in determining the near-add power. The LSR group discontinued monovision sooner than the HSR group, who continued treatment for longer than 4 weeks during the adaptation period much more often for all add ranges. CONCLUSIONS: Practitioners who regard monovision treatment as very successful have somewhat different fitting philosophies than those who regard monovision as unsuccessful. Implementation of highly successful practitioners' fitting techniques may increase success with monovision contact lens fitting.

Adaptation, Ocular↗
PubMed1999

Change in refractive anisometropia in presbyopic adults wearing monovision contact lens correction.

BACKGROUND: Researchers studying the refractive development of infant monkeys suggest that monocular refractive error changes in response to induced ametropia; specifically, slightly blurring one eye may cause a difference to develop between each eye's correction (anisometropia) when none existed before wearing the correction. The important question of whether similar changes occur in humans has not been addressed. METHODS: We compared premonovision correction and the correction after at least 12 months of monovision soft contact lens wear (artificially induced anisometropia prescribed to focus one eye for near and the other for distance so that bifocal glasses are not needed) for 62 healthy predominantly female soft contact lens wearers and (a) 62 age- and sex-matched spectacle wearers and (b) 62 age- and generally sex-matched contact lens wearers. Control patients wore corrections of like power and had similar follow-up periods. RESULTS: Development of anisometropia occurred significantly more frequently among monovision wearers than among spectacle (p = 0.043) or contact lens wearing controls (p = 0.025). Changes in anisometropia greater than or equal to 0.50 D, with amounts up to 1.25 D, occurred in 29% of monovision wearers. CONCLUSIONS: Changes in refractive correction occur for adults who have monocular blur intentionally induced with monovision contact lenses. Similar changes may also occur after refractive surgery if one eye is corrected for a different distance than the other. Care should be taken when counseling presbyopic patients so that they are aware of the possibility of inducing refractive changes after monovision correction.

Adult↗
PubMed1991

In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.

Bryostatin 1 is a macrocyclic lactone protein kinase C (PK-C) activator which has demonstrated promising antileukemic activity in preclinical studies. We have examined the effect of this agent on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) in both log phase and high-density human promyelocytic leukemia cells (HL-60). Exposure of low-density cells to 12.5 nM bryostatin 1 for 24 hr prior to a 4-hr incubation with 1 or 10 microM ara-C resulted in nearly a 2-fold increase in ara-CTP formation. When cells were maintained under high-cell density conditions (e.g. 5 x 10(6) cells/mL) for 24 hr prior to ara-C exposure, a 90% reduction in ara-CTP formation and ara-C DNA incorporation was observed. However, coincubation of high-density cells with bryostatin 1 for 24 hr increased ara-CTP formation 6- to 8-fold, yielding levels essentially equivalent to those achieved in low-density cells. Smaller (but still significant) increases in ara-C DNA incorporation were also noted. Enhancement of ara-CTP formation by bryostatin 1 occurred over a broad ara-C concentration range (0.1 to 100 microM), involved a temperature-dependent process, could not be mimicked by addition of hematopoietic growth factors, and was not related to neutralization of toxic or inhibitory substances in high-density medium. Exposure of cells to bryostatin 1 did not lead to morphologic or functional evidence of HL-60 cell maturation or an increase in cell viability, but did produce a decline in cellular proliferative activity as determined by thymidine and bromodeoxyuridine incorporation and cytofluorometric analysis. Bryostatin 1 did not exert its effects in high-density cells by inhibiting ara-C deamination or by interfering with ara-CTP dephosphorylation, but instead appeared to act by enhancing ara-C phosphorylation. Although cell-free extracts obtained from high-density cells exposed to bryostatin 1 exhibited levels of deoxycytidine kinase activity compared to controls, treated cells did display a significant decline in intracellular dCTP levels (e.g. 0.7 vs 1.3 pmol/10(6)), and nearly a 2-fold increase in ATP and UTP concentrations. Ara-CTP formation was also increased substantially by other PK-C activators including phorbol dibutyrate and mezerein (10-100 nM); this process was inhibited more than 70% by the PK-C inhibitor H-7 (50 microM), but not by the PK-C inhibitors staurosporine, tamoxifen, and HA1004. Finally, coadministration of ara-C and bryostatin 1 resulted in greater than expected inhibitory effects toward HL-60 cell clonogenic growth.(ABSTRACT TRUNCATED AT 400 WORDS)

Antineoplastic Agents↗
PubMed1991

Short course of aerosol pentamidine as treatment of Pneumocystis carinii pneumonia in AIDS.

Since July 1987, 20 HIV-positive patients with Pneumocystis carinii pneumonia (PCP) admitted to the Department of Infectious Diseases, Malmö General Hospital, Sweden have been treated with 10 consecutive days of aerosol pentamidine as sole antimicrobial therapy in a prospective open non-controlled trial. 16 patients (80%) responded to 10 days of 400 mg aerosol pentamidine daily. One patient responded after a prolonged treatment, one patient received simultaneous trimethoprim-sulfamethoxazole due to lack of improvement during aerosol therapy. Two patients died 26 and 41 days after initiation of treatment. No systemic side effects occurred. In conclusion, we found that 10 days of aerosol pentamidine may be a safe and effective treatment of PCP. Controlled studies are needed.

Acquired Immunodeficiency Syndrome↗
PubMed1989

A method for the synchronization of cultured cells with aphidicolin: application to the large-scale synchronization of L1210 cells and the study of the cell cycle regulation of thymidylate synthase and dihydrofolate reductase.

The DNA polymerase alpha inhibitor, aphidicolin, was employed to synchronize large-scale suspension cultures (10(9) cells) of murine L1210 leukemia cells. On the basis of the doubling time and cell cycle distribution for logarithmically growing L1210 cells, a synchronization protocol was devised involving a temporal sequence of two 12-h exposures to aphidicolin, separated by an 6-h interval in drug-free medium. After the second aphidicolin treatment, resuspension of cells into drug-free medium resulted in the rapid onset of DNA synthesis as assessed by [3H]thymidine incorporation and DNA fluorescence with flow cytometry. By 6 h after aphidicolin removal, the cells progressed into the G2-M phase and cell division was initiated. DNA synthesis was minimal during this time and remained low through 9 h when the majority of the cells were in G1 phase. Only low levels of cytotoxicity were observed when L1210 cells were treated with aphidicolin in this fashion. The levels of both thymidylate synthase and dihydrofolate reductase were relatively constant during cell cycle transit, following release from the aphidicolin blockade. Similarly, the levels of the corresponding mRNA transcripts for these enzymes, measured by Northern blot hybridizations, remained essentially unchanged through most of the cell cycle, increasing approximately twofold only as the cells entered G1 phase. Whereas intracellular dihydrofolate reductase catalytic activity was relatively unchanged throughout the cell cycle, as reflected in the metabolism of [3H]folic acid to reduced folate forms, a marked increase in in situ thymidylate synthase activity occurred during S phase that was tightly linked to the rate of DNA synthesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1988

Coordination and reversibility of signals for proliferative activation and interleukin-2 mRNA production in resting human T lymphocytes by phorbol ester and calcium ionophore.

Sequential stimulation and washout procedures were employed to examine the kinetics and reversibility of pharmacologically manipulated second messenger signals mediating phenotypic changes and proliferative activation of resting human T lymphocytes. Phorbol dibutyrate (PDBu) was used to stimulate protein kinase C (Ca2+/phospholipid-dependent enzyme) while ionomycin was used to manipulate intracellular Ca2+ levels. Stimulation by PDBu alone induced phosphorylation of several endogenous substrates and altered expression of phenotypic markers, downregulating expression of CD4 and CD3 while increasing expression of CD2 and the interleukin 2 (IL-2) receptor. Stimulation with ionomycin alone caused an increase in intracellular Ca2+ levels but did not induce proliferation or cause major changes in the expression of phenotypic markers (CD2, CD3, CD4, CD8, IL-2, and transferrin receptors). Analysis of endogenous PDBu stimulated phosphosubstrates indicated that some substrates (pp92, pp82, pp55) underwent dephosphorylation, returning to base-line levels following PDBu removal while others (pp61, pp65) showed only partial dephosphorylation, while one (pp28) remained phosphorylated. Washing ionomycin-stimulated cells resulted in an approximately 75% reduction of intracellular Ca2+. Ionomycin exposure did not alter the affinity (KD = 22.3 +/- 7.4 nM) or number of receptors (53,497 +/- 8,291 receptors/cell) for [3H]PDBu. These data suggest that signals induced by PDBu or ionomycin are reversible following removal of the stimulating agents with respect to proliferative activation of T lymphocytes. Furthermore, a transcriptional mechanism regulating the production of IL-2 mRNA requires simultaneous activation of protein kinase C and elevation of intracellular Ca2+.

Blotting, Northern↗
PubMed1988

Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation.

A full-length human c-myb cDNA clone has been isolated from a CCRF-CEM leukemia cell cDNA library. The plasmid vector contains simian virus 40-derived promotor, splice, and polyadenylation sequences as well as a transcription unit for a dihydrofolate reductase cDNA. We have introduced this construct into Friend erythroleukemia (F-MEL) cells and have isolated a number of clones which contain intact and transcriptionally active human c-myb sequences. F-MEL clones expressing the highest levels of the human c-myb mRNA differentiate poorly in response to dimethyl sulfoxide. Two clones which initially expressed low levels of human c-myb transcripts and which differentiated normally were subsequently inhibited in their ability to differentiate when grown in successively higher concentrations of methotrexate, due to amplification and enhanced expression of plasmid sequences. The inhibitory effect on F-MEL differentiation appeared to be independent of the early decline in c-myc transcripts which were normally regulated in all cases examined. Our results indicate that constitutive expression of a nontruncated human c-myb cDNA can exert profound effects on erythroid differentiation and argue for a causal role of c-myb in the F-MEL differentiation process.

Animals↗
PubMed1987

Allelic variation of the c-raf-1 oncogene in non-Hodgkin's lymphoma.

Polymorphic variation of the c-raf-1 proto-oncogene is reported here for the first time. In a study of 21 individuals, including 17 with non-Hodgkin's lymphoma and three healthy controls, we have identified three c-raf-1 alleles. One variant allele was observed in both a mother and her son, both of whom had lymphoma, but in no other case. The other variant allele was observed in two patients with lymphoma and in a healthy control.

Alleles↗
PubMed1986

Rearrangement and enhanced expression of c-myc oncogene in fresh tumor cells obtained from a patient with acute lymphoblastic leukemia.

Both enhanced and altered expressions of cellular oncogenes have recently been implicated in specific forms of human malignancy (for review: [2, 8]). The fact that certain human tumors have characteristic chromosomal translocations has led to the hypothesis that specific cellular oncogenes may be 'activated' in these genetic recombinations. In a number of human undifferentiated B-cell lymphoma (UBL) cell lines carrying the t(8:14) translocation it has been shown that the human c-myc gene is located on the region of chromosome 8 (8q24), which is translocated to the immunoglobulin heavy-chain (IHC) locus on chromosome 14 [7, 24]. We report here the molecular cloning of the recombination site between c-myc and IHC in fresh uncultured cells obtained from a patient with rapidly progressive and fatal acute lymphoblastic leukemia. The translocation was associated with an enhanced c-myc expression in the tumor cells of this patient.

Base Sequence↗
PubMed1985

Detection of a surface antigen on NIH3T3 cells transfected with a human leukemia oncogene.

This study was conducted to examine the cell surface changes associated with oncogene induced transformation. Using the transfection technique the DNA of a human acute lymphocytic leukemia (ALL) was used to transform murine NIH3T3 cells. Balb/c mice were immunized with these transfectants and their immune splenocytes were used to produce a monoclonal antibody (17-9H3). Antibody 17-9H3 was demonstrated to bind to the cell membranes of transfectants and leukemia cells but not normal 3T3 cells in an enzyme linked immunosorbent assay. Fresh human leukemias, cultured leukemia lines and normal hemopoietic cells were examined with immunoperoxidase staining techniques to determine the specificity of 17-9H3. Our data suggest that the antigen associated with a human acute lymphocytic leukemia oncogene is ubiquitous, distributed among both neoplastic and normal hemopoietic cells. Among fresh human leukemias the antigen appears to be present primarily on fresh null ALLs and chronic myelogenous leukemia (CML) in blast crisis. This antigen was also found to be expressed by the majority of cultured T-cell lines tested.

Animals↗
PubMed1984

Oncogene expression in human leukemia.

The transforming genes of retroviruses (v-onc) are derived from normal cellular genes referred to as proto-oncogenes. These cellular genes have the capacity for conversion to oncogenes (c-onc) that are capable of inducing or maintaining the transformed state when they are overly expressed or altered by mutation or rearrangement. To study the possible involvement of these genes in human leukemia, we have analyzed their expression in a variety of fresh samples. We found that a number of oncogenes are expressed in different leukemic types and that although the transcript size did not vary for each gene, the copy number did. The myc gene (2.4 kb transcript) and the rasHa gene (1.5 kb transcript) were universally expressed. But in contrast to rasHa, the myc signal intensity varied. Myb (4.5 kb transcript) was expressed in all samples except B cell diseases. We detected low levels of abl expression (multiple mRNA species) in all leukemic types analyzed. Sis gene (4.2 kb transcript) expression was restricted to one patient sample with chronic myelogenous leukemia in blast transformation.

Acute Disease↗
PubMed1984

A novel approach to production of antitumor monoclonal antibodies: antibody to a cell surface glycoprotein associated with transformation by a human oncogene.

Transfection is a technique for inducing transformation of normal fibroblasts (NIH 3T3) with DNA (oncogenes) from human tumors. Our goal was to determine if these transformed cells expressed antigens associated with malignancy. NIH 3T3 cells were transfected with DNA fragments from a human acute lymphocytic leukemia (ALL 1-69), and transformed colonies were selected for growth in soft agar. Transfected cells containing human DNA sequences demonstrated by Southern blot analysis were used to immunize Balb/C mice. Monoclonal antibodies were produced and screened for binding to the parental leukemia (ALL 1-69), transfectant (17(2], and 3T3 cells in an enzyme-linked assay. A monoclonal antibody (IgM kappa) designated 17-9H3 bound to ALL 1-69 and secondary transfectant 17(2) but not to NIH 3T3 plasma membranes. Immunoperoxidase staining confirmed this binding pattern and demonstrated that the antigen was expressed on the cell surface. Expression of the antigen by transfectants directly correlated with the presence of a single 6.1 kilobase human DNA sequence. The antibody binding site of the antigen was inactivated by trypsin, glucosidase, and hyaluronidase. Binding of the 17-9H3 antibody was selective for acute lymphocytic leukemias (5/8) and osteogenic sarcomas (33/36), although other tumor types did demonstrate significant binding by immunoperoxidase staining. The majority of normal tissues did not bind 17-9H3 with the exception of some metabolically active cells (renal tubular epithelium, secretory epithelial cells, and cardiac smooth muscle), germ cells, Leydig cells of the testes, and some lymphoid cells. Monoclonal antibodies to oncogene-associated antigens may be potentially useful for cancer diagnosis and therapy and as probes for oncogene isolation.

Animals↗
PubMed1983

Cellular onc genes: their role as progenitors of viral onc genes and their expression in human cells.

Viral transforming (v-onc) genes are derived from cellular (c-onc) genes that are highly conserved among vertebrates. Comparative studies of v-onc and c-onc genes have shed some light on the mechanism leading to formation of the transforming viruses. A specific example of the sis gene is presented here for illustration. Studies on the expression of six c-onc genes in human cells revealed at least three categories of onc genes: (a) those that are universally expressed and probably are important in basic cellular functions, (b) those that are not detectably expressed in the cells examined and may have very transient expression in development, and (c) those that are only expressed in specific cell types and may be important in tissue differentiation. Our studies do not show conclusively a role of these onc genes in human neoplasias.

Animals↗
PubMed1983

Abundant transcription of a cellular gene in T cells infected with human T-cell leukemia-lymphoma virus.

Human T-cell leukemia-lymphoma virus (HTLV) is a type C retrovirus associated with a subtype of mature T-cell malignancy in humans. HTLV also infects normal human cord blood mature T lymphocytes in vitro and induces a number of phenotypic changes in these cells, including their continuous growth and partial or complete independence of T-cell growth factor (TCGF). As part of our initial study designed to analyze gene(s) specifically activated by HTLV infection, we have isolated a recombinant DNA clone by differential screening of a cDNA library made from mRNA of a human T-cell lymphoma cell line producing HTLV. This cDNA identifies a single-copy gene in all human DNAs and a single mRNA species of 2.3 kilobases expressed at several hundred copies per cell in five HTLV-positive neoplastic T-cell lines. In addition, cord blood T lymphocytes infected with HTLV, but not the uninfected counterparts, express high levels of mRNA from this gene. A survey of different human hematopoietic cell types showed that this gene is expressed at low or undetectable levels (less than 10 copies) in human T, B, myeloid, or erythroid cell lines; in moderate amounts in lymphoid precursor (immature) cell lines; and in high amounts in lectin-activated mature T-cells, comparable to those of HTLV-infected T-cell lines. The precise function of this gene has not yet been determined.

Animals↗
PubMed1975

Biochemical profiles of cancer cells: I. Computerized analysis of mouse leukemic cellular RNA on polyacrylamide gels.

Recent studies in this laboratory have been directed at investigating the cellular and subcellular metabolism of RNA in leukemic cells which have been characterized with respect to their degree and type of sensitivity/resistance to specific chemotherapeutic agents. In the present report, electrophoretic patterns on several types of SDS-polyacrylamide gels are presented using total cellular RNA preparations from a subline of L1210 mouse leukemia found to be resistant to cytosine arabinoside (L1210/Ara-C). These studies have been facilitated by using a computerized-spectrophotometric system for quantitative and qualitative comparisons of these profiles. The results suggest that patterns of RNA metabolism may be a useful biochemical test in leukemia.

Animals↗
PubMedDate not supplied

Transformation of NIH 3T3 cells by a human c-sis cDNA clone.

The mechanism of leukaemogenic transformation by human T-cell leukaemia/lymphoma virus (HTLV), a retrovirus implicated in the aetiology of certain adult T-cell leukaemias and lymphomas, is unknown but is conceivably associated with the expression of the cellular analogues of retroviral oncogenes. The HUT-102 cell line, derived from a cutaneous T-cell lymphoma and infected with HTLV, expresses several cellular oncogenes. It is unusual among haemopoietic cell lines in that one of these is c-sis, the gene from which the oncogene v-sis of the simian sarcoma virus was derived, and perhaps the gene for platelet-derived growth factor (PDGF). To explore the possible role of c-sis expression in HTLV-induced disease, we have obtained cDNA clones of c-sis from HUT-102 cells. Here we describe two such clones and report that one of them transforms NIH-3T3 cells. This is the first example of transformation of NIH-3T3 cells by a human onc gene other than c-ras or Blym, as well as the first demonstration of transformation by a human cDNA clone.

Animals↗